In the news release, Biointron Launches RushData, an Integrated High-Throughput Platform for AI-Driven Antibody Discovery, issued 05-Aug-2026 by Biointron over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end:
Biointron Launches RushDATA™, a Wet Lab Validation Platform for AI-Driven Antibody Discovery
- Sequence to data turnaround time of 2 days for cell-free expression or 3 days for CHO cell expression for standardized, structured datasets ready for AI/ML-driven design
- Custom workflows for targets and modalities, with capacity for 10,000+ antibodies expressed per day
- Identify liabilities early with developability assessments to reduce late-stage failure and downstream risk
CAMBRIDGE, Mass., July 28, 2026 /PRNewswire/ — Biointron Biological USA Inc. (“Biointron”), a leading contract research organization specializing in antibody discovery, expression, and optimization for global biotechnology and pharmaceutical companies, today announced the launch of RushDATA™, a new integrated service platform designed to support the growing demands of AI- and machine learning-driven antibody discovery.
As computational antibody design continues to accelerate, AI and ML models are now able to generate hundreds to thousands of candidate antibody sequences in a single design cycle. But while sequence generation has scaled rapidly, experimental validation workflows are often fragmented, with expression, binding characterization, and developability testing performed separately across multiple steps or providers. This traditional approach can take 3-4 weeks or longer, slowing iteration and creating a major bottleneck in design-build-test-learn cycles.
RushDATA™ was developed to close this gap.
Built around Biointron’s sequence to data turnaround time of 2 days for cell-free expression or 3 days for CHO cell expression capability, RushDATA™ enables researchers to move from antibody sequence submission to high-quality experimental data in days. The platform integrates antibody expression, binding analysis, and optional early developability profiling into a single standardized workflow, generating structured datasets that are well suited for AI/ML model training, validation, and optimization.
Designed for speed, scale, and therapeutically relevant data
RushDATA™ leverages CHO cells, the industry gold standard for therapeutic antibody expression, to produce data that is more predictive of downstream performance. CHO-based expression supports human-like post-translational modifications, proper protein folding, and clinically relevant developability characteristics.
RushDATA™ can support capacity for 10,000+ antibodies expressed per day, with standardized workflows and structured outputs designed for both scientists and machine-readable AI pipelines.
Key advantages of RushDATA™ include:
- Sequence to data turnaround time of 2 days for cell-free expression or 3 days for CHO cell expression capability for rapid iteration and screening with custom workflows for targets and modalities
- Standardized, structured AI/ML-ready data from processing 3,000+ molecules per batch in parallel
- Binding characterization using BLI and/or SPR, integrated directly with expression and purity data
- Early developability profiling in selected packages, including:
- Differential scanning fluorimetry (DSF) for thermal stability
- AC-SINS for self-interaction behavior
- Polyspecificity reagent binding (PSR-BVP) for polyreactivity
Flexible service packages
RushDATA™ is available through multiple service options tailored to different stages of antibody discovery:
- Basic – Rapid Screening
Expression, titer, and affinity testing - Standard – Binding Characterization
Expression, concentration, cGE, and affinity testing - Premium – Developability Profiling
Includes early developability assessments with binding characterization
With more than 14 years of experience, service to 3,000+ biopharma companies worldwide, and deep expertise in antibody production and characterization, Biointron continues to expand its platform capabilities to meet the evolving needs of modern biologics discovery.
To learn more about RushDATA™, visit https://www.biointron.com/rushdata or contact Biointron at +1 (732) 790-8340.
About Biointron
Founded in 2012, Biointron is a global antibody discovery CRO trusted by 3,000+ organizations in 20+ countries and regions, including top 20 pharma companies. Our RushDATA™ platform generates wet-lab data for AI-designed antibodies at scale, expressing 10,000+ antibodies a day and delivering binding and developability results in as little as 2 days, ready to feed your models via API. We also offer end-to-end antibody services from discovery to large-scale production, including our CHOK1BN cell line, already supporting partner programs in clinical trials.
For more information about Biointron, contact the company here:
Biointron
+1 (732) 790-8340
info@biointron.com
20 University Road, Suite 500, Cambridge, MA 02138
Correction: The platform name RushData has been corrected to RushDATA™, and listed features have been expanded for clarity and accuracy. The headline has also been updated.
View original content to download multimedia:https://www.prnewswire.com/news-releases/biointron-launches-rushdata-an-integrated-high-throughput-platform-for-ai-driven-antibody-discovery-302843817.html
SOURCE Biointron
